Is legacy tech or the target to blame in Pfizer’s Phase III lung cancer miss?

Pfizer's Phase III miss for an ITGB6 antibody-drug conjugate — the first pivotal readout from the ADC pipeline it inherited in its 2023 Seagen acquisition, and the latest in a run of setbacks for that pipeline — raises the question of whether the legacy linker-payload tech or the target itself is to blame. The week's biggest mover ran the other way: Definium rose 50% after DT120 hit its endpoints in a Phase III major depression trial.

Late Monday, Pfizer Inc. (NYSE:PFE) announced sigvotatug vedotin missed the overall survival primary endpoint versus chemotherapy in the Phase III SigVie-002 study in advanced, metastatic non-squamous non-small cell lung cancer (NSCLC) patients with one or more lines of prior therapy...